Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D B Mark

Showing results (151-160 of 178) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|January 15, 2000
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingE J Topol, D B Mark, A M Lincoff, et al.
Circulation|November 1, 1987
The changing survival benefits of coronary revascularization over timeD B Pryor, F E Harrell, J S Rankin, et al.
JAMA|April 14, 1989
The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspectiveR M Califf, F E Harrell, K L Lee, et al.
Journal of the American College of Cardiology|May 1, 1991
Restenosis after coronary angioplasty: an overviewR M Califf, D F Fortin, D J Frid, et al.
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Circulation|May 1, 1994
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplastyD B Mark, C L Nelson, R M Califf, et al.
Circulation|November 11, 1991
Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgeryL R Smith, F E Harrell, J S Rankin, et al.
The American Journal of Cardiology|June 1, 1986
A simplified method to predict occurrence of complete heart block during acute myocardial infarctionG A Lamas, J E Muller, Z G Turi, et al.
Circulation|November 11, 1992
Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-upL H Muhlbaier, D B Pryor, J S Rankin, et al.
Pageof 18

Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|January 15, 2000
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingE J Topol, D B Mark, A M Lincoff, et al.
Circulation|November 1, 1987
The changing survival benefits of coronary revascularization over timeD B Pryor, F E Harrell, J S Rankin, et al.
JAMA|April 14, 1989
The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspectiveR M Califf, F E Harrell, K L Lee, et al.
Journal of the American College of Cardiology|May 1, 1991
Restenosis after coronary angioplasty: an overviewR M Califf, D F Fortin, D J Frid, et al.
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Circulation|May 1, 1994
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplastyD B Mark, C L Nelson, R M Califf, et al.
Circulation|November 11, 1991
Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgeryL R Smith, F E Harrell, J S Rankin, et al.
The American Journal of Cardiology|June 1, 1986
A simplified method to predict occurrence of complete heart block during acute myocardial infarctionG A Lamas, J E Muller, Z G Turi, et al.
Circulation|November 11, 1992
Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-upL H Muhlbaier, D B Pryor, J S Rankin, et al.
Pageof 18